Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.355 USD | -3.22% | -11.27% | +129.66% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+129.66% | 880M | |
+18.98% | 125B | |
+14.16% | 108B | |
-3.60% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.48% | 16.54B | |
-11.98% | 16.5B | |
+2.99% | 13.39B | |
+27.69% | 11.1B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Transcript : Arcutis Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024